ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet Oncol · 2026-07-01

In 110 patients with dMMR/MSI-H locally advanced colorectal cancer, adding celecoxib to neoadjuvant toripalimab raised pathological complete response to 89% vs 69% with toripalimab alone (difference 19 points; p=0·014), with similar grade 3 toxicity (5% vs 7%).

RCTn = 110
Hu et al. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial
Oncology · JAMA Oncol · 2026-02-01

Post hoc analysis of 940 patients with stage III colon cancer: postoperative ctDNA positivity predicted worse DFS (aHR 6.12). Celecoxib was associated with better DFS in ctDNA-positive patients (aHR 0.61) but not ctDNA-negative ones; interaction not significant.

Secondary analysisn = 940
Zhang et al. Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.